Search results
Results from the WOW.Com Content Network
Phencyclidine (PCP) is believed to be the first arylcyclohexylamine with recognized anesthetic properties, but several arylcyclohexylamines were described before PCP in the scientific literature, beginning with PCA (1-phenylcyclohexan-1-amine) the synthesis of which was first published in 1907. PCP itself was discovered in 1926 but not ...
Download as PDF; Printable version; ... The complete data for Phencyclidine General information ... a Abbreviations: PCP Synonyms: Angel {dust/hair/mist} ...
4-Phenyl-4-(1-piperidinyl)cyclohexanol, also known as PPC, is an organic chemical which is a metabolite of phencyclidine (PCP). [1] It can be detected in the hair of PCP users. [2] PPC has been shown to cause increases in locomotor activity in lab mice. [3]
PCP site 2 is a binding site that was identified as a high-affinity target for phencyclidine (PCP), an anesthetic and dissociative hallucinogen that acts primarily as an NMDA receptor antagonist. [1]
The respiratory tract antimicrobial defense system is a layered defense mechanism which relies on components of both the innate and adaptive immune systems to protect the lungs and the rest of the respiratory tract against inhaled microorganisms.
Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. [1] [4] PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior.
PCPr is an arylcyclohexylamine dissociative anesthetic drug with hallucinogenic and stimulant effects. It is around the same potency as phencyclidine, although slightly less potent than the ethyl homologue eticyclidine, [1] and has reportedly been sold as a designer drug in Germany and other European countries since the late 1990s.
Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...